Zacks: Analysts Anticipate G1 Therapeutics Inc (NASDAQ:GTHX) to Post -$0.85 Earnings Per Share

Brokerages predict that G1 Therapeutics Inc (NASDAQ:GTHX) will announce ($0.85) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($0.92). G1 Therapeutics reported earnings of ($0.59) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 44.1%. The firm is scheduled to report its next earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that G1 Therapeutics will report full-year earnings of ($3.20) per share for the current fiscal year, with EPS estimates ranging from ($3.48) to ($2.96). For the next fiscal year, analysts anticipate that the firm will post earnings of ($4.09) per share, with EPS estimates ranging from ($4.57) to ($3.52). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.09).

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of G1 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $38.00 to $45.00 in a report on Thursday, August 8th. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. ValuEngine raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $61.00.

GTHX traded up $6.56 on Friday, reaching $38.01. The stock had a trading volume of 287,384 shares, compared to its average volume of 387,573. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $69.57. The company has a 50-day moving average price of $27.30. The company has a market cap of $1.12 billion, a P/E ratio of -14.85 and a beta of 2.66.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of G1 Therapeutics by 0.6% during the first quarter. FMR LLC now owns 5,611,235 shares of the company’s stock worth $93,147,000 after purchasing an additional 33,481 shares in the last quarter. BlackRock Inc. increased its stake in shares of G1 Therapeutics by 27.4% during the second quarter. BlackRock Inc. now owns 2,468,415 shares of the company’s stock worth $75,681,000 after purchasing an additional 530,999 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of G1 Therapeutics by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,976,615 shares of the company’s stock worth $60,603,000 after purchasing an additional 100,523 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of G1 Therapeutics by 27.8% during the second quarter. JPMorgan Chase & Co. now owns 1,429,138 shares of the company’s stock worth $44,446,000 after purchasing an additional 310,614 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of G1 Therapeutics by 4.2% during the second quarter. Northern Trust Corp now owns 302,452 shares of the company’s stock worth $9,273,000 after purchasing an additional 12,300 shares in the last quarter. 73.58% of the stock is owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Recommended Story: Buy-Side Analysts

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.